Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%

被引：0
|
作者：
Merker, Ludwig
Lund, Soren S.
Hantel, Stefan
Salsali, Afshin
Kim, Gabriel
Broedl, Uli C.
Woerle, Hans J.
Hach, Thomas
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1079-P
引用
收藏
页码：A280 / A281
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of empagliflozin in younger overweight/obese patients with Type 2 diabetes with HbA1c ≥8%
    Merker, L.
    Lund, S. S.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Broedl, U. C.
    Woerle, H. J.
    Hach, T.
    [J]. DIABETIC MEDICINE, 2015, 32 : 90 - 90
  • [2] HbA1c Response to Open-Label (OL) Empagliflozin (EMPA) with Metformin (MET) in Patients with Type 2 Diabetes (T2DM)
    Schernthaner, Guntram
    Tinahones, Francisco J.
    Goetz, Sophia
    Lee, Christopher
    [J]. DIABETES, 2017, 66 : A345 - A346
  • [3] Consistent Weight Changes Irrespective of Baseline HbA1c with the Combination of Empagliflozin/Linagliptin (EMPA/LINA) in Subjects with Type 2 Diabetes (T2DM)
    Barnett, Anthony H.
    Defronzo, Ralph A.
    Lewin, Andrew
    Patel, Sanjay
    Liu, Dacheng
    Kaste, Renee
    Broedl, Uli C.
    Lee, Christopher
    [J]. DIABETES, 2015, 64 : A656 - A656
  • [4] Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM)
    Kohler, S.
    Kaspers, S.
    Salsali, A.
    Zeller, C.
    Woerle, H. -J.
    [J]. DIABETOLOGIA, 2016, 59 : S26 - S26
  • [5] Modelling HbA1c Trajectory in Patients with Type 2 Diabetes Mellitus (T2DM)
    Mcewan, Phil
    Fellows, Jonathan
    Yapp, Rhiannon
    Bergenheim, Klas
    Qin, Lei
    Varol, Nebibe
    Bennett, Hayley
    Gordon, Jason
    [J]. DIABETES, 2016, 65 : A322 - A322
  • [6] Treatment Progression and Impact of HbA1C in Type 2 Diabetes (T2DM) Patients
    Dibello, Julia R.
    Levy, Brian
    Mehra, Maneesha
    [J]. DIABETES, 2010, 59 : A623 - A624
  • [7] Safety and tolerability of empagliflozin (EMPA) in phase III trials and their extensions in patients with type 2 diabetes (T2DM)
    Roden, M.
    Merker, L.
    Christiansen, A. V.
    Roux, F.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Lund, S. S.
    Hach, T.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETOLOGIA, 2014, 57 : S325 - S326
  • [8] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2015, 64 : A302 - A303
  • [9] HbA1c and Prediction of Type 2 Diabetes (T2DM) in Children and Adults
    Vijayakumar, Pavithra
    Nelson, Robert G.
    Hanson, Robert L.
    Knowler, William C.
    Sinha, Madhumita
    [J]. DIABETES, 2016, 65 : A65 - A65
  • [10] Slope of Decline in HbA1c with Empagliflozin Appears to Be Greater than the Slope with Sitagliptin or Glimepiride in Patients with Type 2 Diabetes (T2DM)
    Defronzo, Ralph A.
    Elsasser, Ulrich
    Lund, Soren S.
    Hach, Thomas
    [J]. DIABETES, 2015, 64 : A331 - A332
12345